Business Context and Reporting Period
Company: Septerna, Inc. (SEPN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Septerna is a clinical-stage biotechnology company developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company focuses on endocrinology, immunology/inflammation, and metabolic diseases. It is an Emerging Growth Company and Smaller Reporting Company.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenue | $45,951 | $1,075 |
| Net Loss | $(48,879) | $(71,798) |
| Operating Expenses | $114,248 | $81,898 |
| Research & Development (R&D) | $97,584 | $65,337 |
| General & Administrative (G&A) | $29,164 | $16,561 |
| Cash, Cash Equivalents & Marketable Securities | $548,700 | $356,824 (Current) + $69,866 (Non-current) |
| Accumulated Deficit | $(167,253) | $(118,374) |
Note: Revenue consists primarily of collaboration and research service fees. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased by $44.9 million (4,174%) driven by a $195.0 million upfront payment from a new collaboration with Novo Nordisk A/S (Novo) and a $12.5 million milestone payment from Vertex Pharmaceuticals.
- Reduced Net Loss: Net loss decreased by $22.9 million (32%) compared to 2024, despite higher operating expenses, due to the significant revenue recognition and a $12.5 million gain on the sale of a non-financial asset (Vertex milestone).
- Increased R&D Spend: R&D expenses rose by $32.2 million, primarily due to increased direct costs for the MRGPRX2 program (SEP-631) and "Other programs," as well as higher payroll costs.
- Liquidity Position: Cash and marketable securities increased significantly to $548.7 million, bolstered by the Novo upfront payment and strong interest income ($19.5 million).
Guidance, Outlook, and Management Commentary
Strategic Partnerships
- Novo Nordisk Collaboration: Entered in May 2025 (effective July 2025). Septerna received a $195.0 million upfront payment. The collaboration covers four R&D programs targeting metabolic diseases (GLP-1, GIP, glucagon receptors). Septerna is eligible for up to ~$498.0 million in milestones per program and tiered royalties.
- Vertex Pharmaceuticals: Received a $12.5 million milestone payment in August 2025 related to a prior asset purchase agreement. The research service agreement expired in September 2025.
Pipeline Updates
- SEP-786 (PTH1R Agonist): Discontinued in February 2025 following Phase 1 observations of elevated unconjugated bilirubin (UGT1A1 inhibition). A next-generation candidate, SEP-479, was selected in September 2025. Phase 1 trials for SEP-479 are planned for the first half of 2026 in Australia.
- SEP-631 (MRGPRX2 NAM): Positive Phase 1 results presented in March 2026. The drug showed safety comparable to placebo and substantial inhibition of skin wheals. Phase 2b trials for Chronic Spontaneous Urticaria (CSU) are planned for the second half of 2026.
- TSHR NAM: Preclinical development continues for Graves' disease and Thyroid Eye Disease (TED).
Liquidity and Outlook
Management expects cash, cash equivalents, and marketable securities of $548.7 million to fund operations and capital expenditures at least into 2029. The company anticipates continued net losses as it advances clinical trials and expands its pipeline.
Risks and Contingencies
- Development Risk: High risk of failure in clinical trials; SEP-786 discontinuation highlights safety risks.
- Regulatory Risk: Dependence on FDA/EMA approvals; potential for delays in clinical trial initiation or enrollment.
- Third-Party Reliance: Reliance on CROs and CMOs, including entities in China (e.g., WuXi), subject to geopolitical risks and the BIOSECURE Act.
- Intellectual Property: Risks related to patent validity, enforcement, and third-party infringement claims.
Key Facts for Investor Verification
- Runway: Verify the $548.7 million cash balance and the management projection of funding operations through 2029.
- Novo Collaboration Terms: Confirm the $195.0 million upfront payment recognition and the potential for ~$498.0 million in milestones per R&D program.
- SEP-479 Timeline: Monitor the initiation of the Phase 1 trial in Australia (planned H1 2026) and topline data release (planned late 2026/early 2027).
- SEP-631 Progress: Track the initiation of the Phase 2b global study for CSU (planned H2 2026) following positive Phase 1 data.
- Discontinued Program: Understand the rationale for discontinuing SEP-786 (UGT1A1 inhibition) and the preclinical validation of the replacement candidate, SEP-479.
- Geopolitical Exposure: Assess the impact of the BIOSECURE Act and U.S.-China trade tensions on the company's reliance on Chinese CMOs/CROs.